# Aaron Lisberg

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/aaron-lisberg/

## Facts

| Field | Value |
| --- | --- |
| Citations | 10,151 |
| Field | Cancer Immunotherapy and Biomarkers |
| h-index | 28 |
| i10-index | 54 |
| Last Known Institution | APLA Health |
| OpenAlex ID | https://openalex.org/A5078435189 |
| ORCID iD | 0000-0003-3048-4352 |
| Works | 199 |

## Researcher papers

- [RETRACTED ARTICLE: Pluripotency of mesenchymal stem cells derived from adult marrow](https://scholariq.org/papers/retracted-article-pluripotency-of-mesenchymal-stem-cells-derived-from-adult/)
- [Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial](https://scholariq.org/papers/previous-radiotherapy-and-the-clinical-activity-and-toxicity-of-pembrolizumab-in/)
- [A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC](https://scholariq.org/papers/a-phase-ii-study-of-pembrolizumab-in-egfr-mutant-pd-l1-tyrosine-kinase-inhibitor/)
- [EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer](https://scholariq.org/papers/egfr-mutation-subtypes-and-response-to-immune-checkpoint-blockade-treatment-in/)
- [Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study](https://scholariq.org/papers/datopotamab-deruxtecan-versus-docetaxel-for-previously-treated-advanced-or/)
- [Viral oncoprotein antibodies as a marker for recurrence of Merkel cell carcinoma: A prospective validation study](https://scholariq.org/papers/viral-oncoprotein-antibodies-as-a-marker-for-recurrence-of-merkel-cell-carcinoma/)
- [First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2–Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non–Small-Cell Lung Cancer: TROPION-PanTumor01](https://scholariq.org/papers/first-in-human-phase-i-dose-escalation-and-dose-expansion-study-of-trophoblast/)
- [Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2– and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study](https://scholariq.org/papers/datopotamab-deruxtecan-in-advanced-or-metastatic-hr-her2-and-triple-negative/)
- [Spatial mapping of mitochondrial networks and bioenergetics in lung cancer](https://scholariq.org/papers/spatial-mapping-of-mitochondrial-networks-and-bioenergetics-in-lung-cancer/)
- [Datopotamab Deruxtecan in Advanced or Metastatic Non–Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study](https://scholariq.org/papers/datopotamab-deruxtecan-in-advanced-or-metastatic-non-small-cell-lung-cancer-with/)
- [Brief Report: The Genomic Landscape of Small Cell Lung Cancer in Never-Smoking Patients](https://scholariq.org/papers/brief-report-the-genomic-landscape-of-small-cell-lung-cancer-in-never-smoking/)

## Researcher topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)

## Researcher university

- [APLA Health](https://scholariq.org/institutions/apla-health/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.